Compare SIMO & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIMO | ACAD |
|---|---|---|
| Founded | 1995 | 1993 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.8B |
| IPO Year | 2005 | 2000 |
| Metric | SIMO | ACAD |
|---|---|---|
| Price | $228.05 | $21.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 22 |
| Target Price | ★ $118.13 | $30.55 |
| AVG Volume (30 Days) | 804.9K | ★ 1.3M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | $42.27 | $18.80 |
| Revenue Next Year | $12.78 | $11.70 |
| P/E Ratio | $36.09 | ★ $9.80 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $51.79 | $14.45 |
| 52 Week High | $229.32 | $28.35 |
| Indicator | SIMO | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 89.02 | 48.06 |
| Support Level | $81.19 | $21.51 |
| Resistance Level | N/A | $22.03 |
| Average True Range (ATR) | 11.70 | 0.61 |
| MACD | 9.85 | 0.05 |
| Stochastic Oscillator | 97.39 | 44.95 |
Silicon Motion Technology Corp is engaged in developing NAND flash controllers for SSDs and other solid state storage devices. Its only operating segment is to develop NAND flash controllers and SSDs solutions. The company derives revenue from product categories such as Mobile Storage, Mobile Communications, and others. Silicon's geographical segments are Taiwan, the United States, Korea, China, Singapore, Malaysia, and others. The company products are used in Personal Computing, Smartphone/Tablet/CE, Flash Card/USB Flash Drive, Industrial and Embedded, Automotive, and Enterprise and Data centers.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.